Physician profile
Michael Justin
NPI 1023196904
$27,686.64
in general payments reported to CMS, 2019-2025
52 companies · $4,983 in 2025
The $4,983 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,825 · 2020: $3,119 · 2021: $3,814 · 2022: $3,620 · 2023: $3,817 · 2024: $4,508 · 2025: $4,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,208.21 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,610.03 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $3,246.66 | 2019-2025 | |
| Pfizer INC. | $2,283.29 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $2,226.47 | 2019-2025 | Spravato |
| Lilly USA, LLC | $2,042.45 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $1,648.91 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,532.06 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,086.41 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Otsuka America Pharmaceutical, INC. | $1,074.21 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,034.70 | 2022-2025 | Caplyta |
| Amgen INC. | $864.72 | 2019-2025 | Otezla, Repatha, Repatha |
| Vanda Pharmaceuticals INC. | $599.25 | 2024-2025 | Fanapt, Hetlioz |
| Horizon Therapeutics Plc | $482.35 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $473.00 | 2021-2024 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $420.07 | 2021-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Justin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.